The Sho must go on!!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I do believe the band is warming up and it is playing our tune..
ENTB = TO DA MOON!!
Getting ready to bust a move.
ENTB = STRONG BUY $$$$$$$$$$$$$$
I agree... Just the beginning for these meds.. Much more in pipeline..
ENTB = TIME IS NOW TO GET IN...
ENTB = WINNIGN TEAM $$$$$$$$$$$$$$$
David R. Koos, PhD, DBA Chairman
David Koos is the Founder, Chairman & CEO of Entest BioMedical Inc. Dr. Koos has over 26 years of investment banking and venture capital experience with a primary focus on fully reporting medical and biotechnology ventures. He holds a Ph.D. degree in Sociology and a Doctor of Business Administration in Finance. Additionally, he has authored / co-authored several peer reviewed journal articles primarily on biotechnology related subjects.
Feng Lin, MD, PhD - Director of Research
Dr. Feng Linhas a strong background in cell biology, cancer biology and therapy. He also has extensive experience with tissue imaging, and stem cell differentiation. Previously, Dr. Lin was a Senior Research Scientist, Research & Development with Inovio BC, San Diego and Postdoctoral Fellow in the Burnham Institute for Medical Research, La Jolla. He received his M.D. from Central South University Xiangya School of Medicine, Changsha, China, along with a M.S. Biochemistry & Molecular Biology and a Ph.D. Hematology & Physiology from the same institution. Dr. Lin's research work has been widely published in international scientific journals.
Back to the Top
Scientific Advisors
Brian Koos, M.D., D.Phil.
Professor of Obstetrics and Gynecology
David Geffen School of Medicine
University of California at Los Angeles (UCLA)
Dr. Koos is an internationally-recognized clinician-scientist who has published in diverse areas ranging from gestational diabetes to circulating endothelial progenitor cells, to adenosine receptors. To date he has 52 publications on Pubmed. He is board certified in maternal and fetal medicine, as well as obstetrics and gynecology. Dr. Koos has a clinical interest in Amniocentesis, Chorionic Villi Sampling, Clinical Trials, Early Amniocentesis, External Cephalic Version, Fetal Diagnostic, General Obstetrics, Genetics, High Risk Pregnancy, Maternal Fetal Medicine, Obstetrical Ultrasound, and Recurrent Pregnancy Loss. He obtained his MD from Loma Linda University in 1974, his internship and residency were at the Harvard Affiliate Brigham and Womens Hospital from 1975-1979. He received a Doctor of Philosophy (D.Phil.) degree in 1982 from Oxford University and a Fellowship in Maternal-Fetal Medicine at USC from 1982-1983.
Brian Koos CV
Back to the Top
Ewa Carrier, M.D.
Associate Professor of Clinical Medicine and Pediatrics
University of California San Diego (UCSD)
Blood and Marrow Transplant Program
Dr. Carriers research focuses on stem cell biology and its transplantation to cancer and organ repair. She focuses on the properties of pluripotent stem cells, including embryonic, fetal, mesenchymal and bone marrow stem cells, to generate differentiation protocols for the treatment of a variety of disorders. Clinically, Dr. Carrier works on multiple protocols related to stem cell transplant for cancers, such as leukemias, lymphomas and multiple myeloma as well as autoimmune diseases. She participates in the protocols within the NIH-sponsored Clinical Trial Network, and is a member of NIH-funded national consortium to treat autoimmune diseases with stem cells.
Ewa Carrier CV
Back to the Top
Steven Josephs, Ph.D.
Chief Science Officer
Therinject LLC, San Diego, CA
Dr. Josephs has 34 years of experience in research and clinical product development and production for biologics, gene therapy and medical devices. He has previously served as Director of Research and Development for Therapheresis, Inc., Head of Virology and Senior Research Scientist for Baxter Healthcare Corporation, and Director of Molecular Biology at Universal Biotechnology, Inc. where Dr. Josephs directed a group performing contract molecular biology services for government and private industry. Dr. Josephs has also served for the National Cancer Institute, where his duties included studies of the human T-cell leukemia virus as well as sequence determination and functional analyses of HIV. Dr. Josephs holds a B.A. in Chemistry, a Ph.D. in Chemistry and has been granted a Professional Certificate in Drug Development and an ADMET process certificate by the University of California, San Diego. He has also earned a Master of Science in Science Teaching.
Steven Josephs, Ph.D. CV
Back to the Top
Vladimir Bogin M.D.
Partner and CEO
Cromos Pharma, LLC
3233 Wildwood Drive
Longview, WA 98632
Dr. Bogin is currently the President and CEO of Cromos Pharma, a contract research organization that specializes in biopharmaceutical clinical outsourcing into areas with the most compelling environment for biopharmaceutical research: Russia and Eastern Europe. From 2008 to 2009 he was also the Director of Boehringer Ingelheim (a privately held pharmaceutical company) where he was in charge of the phase IV program for Dabigatran Etexilate. While first being published in 1995 on the subject of liver care, he has continuously spanned his focus and research capturing the therapies for HIV, liver failure, Budd-Chirari Syndrome, Nontropical Pyomyositis, donor transplantations, endometrial regenerative cells (ERC), exosomes as a tumor immune escape mechanism, atrial fibrillation, COPD, and most recently left atrial enlargement. Dr. Bogin studied medicine at the Yale University School of Medicine and the University of Rochester School of Medicine and Dentistry.
Vladimir Bogin M.D. CV
Back to the Top
Gregory C. McDonald, D.V.M.
Principal Veterinarian
McDonald Animal Hospital
225 South Milpas Street
Santa Barbara, CA 93103
Dr. McDonald is a well respected veterinarian with over 30 years of clinical veterinary experience. He received his Doctor of Veterinary Medicine degree (DVM) from Ohio State University in 1979. Currently he is the principal veterinarian of the McDonald Animal Hospital, which he founded over 24 years ago. His background includes both clinical and research aspects of cancer therapy. His practice includes veterinary applications of stem cell therapies, as well as traditional veterinary medicine. Dr. McDonald has authored numerous publications on various aspects of veterinary care.
Gregory C. McDonald CV
Back to the Top
Brenda S. Phillips, D.V.M.
Medical Oncologist, Part-Owner
Veterinary Specialty Hospital of San Diego
10435 Sorrento Valley Rd.
San Deigo, CA 92121
Dr. Phillips has extensive experience with veterinary oncology. She received her Doctor of Veterinary Medicine in 1992 from Michigan State University, College of Veterinary Medicine. Dr. Phillips is currently a Medical Oncologist and part-owner of the Veterinary Specialty Hospital of San Diego ranging in responsibilities from management of medical oncology patients, clinical trials investigator, instruction of veterinary student externs and veterinary interns, and is also the internal medicine resident. She currently holds a chair position on the client experience committee. She is very active with her research activities, publications, board and committee memberships, presentations and teachings.
ENTB == Given the team's dedication and focus on the advancement of Immuno-Therapeutic Cancer Vaccine, Entest expects to generate near-term revenue, while creating substantial value for shareholders $$$$$$$$$$$$$$$$$$.
ENTB = Entest BioMedical Inc. is a biomedical research company specializing in new procedures, treatments and medical devices that not only achieve measurable results, but also improve the quality of life for patients.
Entest BioMedical sees the acquisition of veterinary clinics and the establishment of a veterinary oncology center as cornerstones to its business model. Veterinary clinics are believed to bring near term revenue to the company, as well as play a strong roll in product distribution as the Company brings products to market.
NOT GONNA MAKE IT... 5'S ARE ON THE WAY OUT!!!
ENTB = Currently, Entest is focused on significant therapeutic therapies that show promise for the development of under-served market niches with potential high demand.
Fire at will!!!
ENTB = Levels will move fast!!!!
I will be jumpin in.. Orders have been placed... Let's get this party started..
I'LL be herdin shares my friend.. Gonna make a bundle on this baby.
ENTB == STRONG BUY -- BEST GET IN EARLY TOMORROW
Don't think these levels will last long.. $$$$$$$$$$$$$$ ;)
Let's get ready to ride this drive... Don't think we have to worry about a fade..
ENTB ==== EXPLOSION WILL BE HEARD BY THOSE WHO HAVE MISSED THEIR SHOT...
Don't think we will have to wait for 5 years Jack..
ENTB = STRONG BUY NOW... HAVE SHARES WILL RUN $$$$$$$$$$$$
Get ready... LOAD UP
ENTB = EXPLOSION!!!
LOOKING TO SEE A 10 BAGGER!! $$$$$$$$
This is going to be HUUUUGGGGEEEE!!!
Numbers are lining up... Sorry for those who miss this...NAHHHH
I am LOADING UP!!!!
ENTB=== STRONG BUY $$$$$$$$$$$$
Support has sustained us now...
This thing is GOING TO RUN HARD.... STRONG BUY $$$$$$$$
The cycle has begun!
TIME TO BUY ++++++++SHARES at these levels...$$$$$$$$$$$$
Those who wait on these levels will be crying in the wind!!!
GO ENTB = STRONG BUY!!!!
ENTB = BOTTOM RESISTANCE HAS BEEN MET.
DO NOT MISS THIS RUN >>>> INTEREST IS BUILDING.
Time to get in NOW!!!!
ENTB = STRONG BUY AT THESE LEVELS $$$$$$
NOT GOING TO LAST LONG >>>>>>>
BUY BUY BUY BUY $$$$$$$$
ENTB = DO NOT WAIT TIL TOMORROW = STRONG BUY
Looking good!!
ENTB IS ABOUT TO EXPLODE!!!
ENTB = STRONG BUY $$$$$$$
ENTB == Bottom has hit...
STRONG BUY AT THESE LEVELS --- THIS PUPPY WILL RUN
ENTB $$$$$ TIME IS NOW OR GET LEFT BEHIND $$$$$$
Thanks muga... Lookin at this hard... :)
ENTB = CANCER DRUGS FOR BOTH HUMANS AND CANINES.
VET CLINICS WILL BE USING THIS DRUGS SOON >>>>>>>
"to develop and commercialize stem cell based therapies, medical devices and medical testing procedures."
NEWS FROM KOOS IS COMING!!!!!
ENTB = STRONG BUY!!!!! STOCK IS READY FOR HUGH UP SWING
ENTB = STOCK READY TO EXPLODE
STRONG BUY $$$$$$ LOWEST LEVELS HAVE BEEN TAKEN
Thanks Jack; Looking at a good RUN TO COME!!!!
ENTB = STRONG BUY $$$$$$$$$$
ENTB = INDICATORS SHOW A RUN IS EMINENT = STRONG BUY AT THESE LEVELS ++++$$$$$$$$$$$$
Oh yes! We are in for a good ride Grouse. Good to see you man!
Good things coming for LVVV and the family..
Thanks man, I will check this out and put it on the radar.
LVVV --- Looking for success!
Hey Yeardman, have you tried the Adia probiotic? Looks like a good thing.
Do the distributors of the energy chews have access to Adia?
Yeah Doc, it would be a good fit. I would like to try some myself.
Has anyone been using Adia probiotics? Looks like a good product.
Like it Jesse, Like it!!!!
Good post!!!
Just spoke to my local store. No Livewire in store yet; however they have them at their warehouse and are waiting on delivery. They will special order them for me or I was instructed to go online to get my order in; response has been good. They are very excited about offering Livewire products..
This enthusiasm from the store seems extremely positive. I cannot wait to see what happens next..
Well jack it looks as if you were TOTALLY correct here!!!!
KOOS has dropped the ball and left all with empty hands...
Koos has Dropped the Ball!! BMSN going to Trips!!! 000's!!! frown
R/S Coming!!! frown
www.otcmarkets.com/content/doc/otcqb-fact-sheet.pdf
Quote:
• Bid Test: All current OTCQB companies that
do not meet the minimum bid test (minimum
bid price of $0.01 per share as of the close of
business for at least one of the previous thirty
consecutive calendar days) will be removed
from OTCQB beginning May 1 .
Quote:
SEC Reporting Companies
Initial Requirements
• Meet an initial bid price test of $0.01 as of the close of business for each of the previous 30 calendar days
• Complete and submit OTCQB Application and applicable fees
• Be current in all periodic reporting requirements on EDGAR (or for companies not required to file on EDGAR, post
SEC disclosure on the OTC Markets website)
• Post on the OTC Markets website:
4OTCQB Initial Certification (see below for details on Certification requirements)
Ongoing Requirements
• Meet an ongoing minimum bid price test of $0.01 as of the close of business for at least one of every 30 calendar days
• Post current SEC disclosure on EDGAR, or for companies that do not file on EDGAR, post current SEC disclosure on
the OTC Markets website
• Post on the OTC Markets website: